Addressing buprenorphine supply barriers: A guidance commentary

Area of Science:

• Pharmacology
• Public Health Policy
• Regulatory Affairs

Background:

• Supply-side constraints currently limit buprenorphine availability in pharmacies.
• Federal regulations and opioid litigation have restricted pharmaceutical distribution and dispensing.
• Existing solutions have not adequately improved access to medications for opioid use disorder (MOUD).

Purpose of the Study:

• To propose a novel solution to overcome supply-side limitations for buprenorphine.
• To explore the potential of Drug Enforcement Administration (DEA) guidance letters in improving MOUD access.
• To address concerns regarding liability and DEA scrutiny in buprenorphine distribution.

Main Methods:

• Analysis of existing DEA guidance letter mechanisms.
• Proposal for a specific DEA guidance letter addressing buprenorphine distribution.
• Examination of legal precedent and regulatory interpretations.

Main Results:

• DEA guidance letters offer a direct communication channel for regulatory clarity.
• A targeted guidance letter could alleviate wholesaler and pharmacy concerns about increased scrutiny.
• Clarification on buprenorphine's status relative to "highly diverted" substances is proposed.

Conclusions:

• A DEA guidance letter can be an actionable strategy to reduce supply-side limitations for buprenorphine.
• Such guidance can provide assurance to distributors and pharmacies, encouraging increased MOUD availability.
• This approach supports the broader goal of enhancing access to medications for opioid use disorder.